Predictive Value of Early MRI Measures for Long-Term Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis Receiving IFN β-1a SC tiw or IFN β-1a IM qw: Post Hoc Analyses of the EVIDENCE Study

被引：0
|
作者：
Coyle, Patricia [3 ]
Freedman, Mark [5 ,6 ]
Dangond, Fernando [1 ]
Fang, Juanzhi [2 ]
Reder, Anthony [4 ]
机构：
[1] EMD Serono Inc, Billerica, MA USA
[2] EMD Serono Inc, Rockland, MA USA
[3] SUNY Stony Brook, Med Ctr, Stony Brook, NY 11794 USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Univ Ottawa, Ottawa, ON, Canada
[6] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6.189
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The long-term safety and tolerability of high-dose interferon β-1a in relapsing-remitting multiple sclerosis:: 4-year data from the PRISMS study
    Gold, R
    Rieckmann, P
    Chang, P
    Abdalla, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (08) : 649 - 656
  • [32] No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
    Kappos, Ludwig
    Havrdova, Eva
    Giovannoni, Gavin
    Khatri, Bhupendra O.
    Gauthier, Susan A.
    Greenberg, Steven J.
    You, Xiaojun
    Wang, Ping
    Giannattasio, Giorgio
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : 1736 - 1747
  • [33] Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis
    Szczucinski, A
    Losy, J
    FOLIA NEUROPATHOLOGICA, 2004, 42 (01) : 15 - 18
  • [34] Peginterferon β-1a provides improvements in clinical and radiological disease activity in relapsing-remitting multiple sclerosis: year 1 findings from the phase 3 ADVANCE study
    Calabresi, P.
    Kieseier, B.
    Arnold, D.
    Balcer, L.
    Boyko, A.
    Pelletier, J.
    Liu, S.
    Zhu, Y.
    You, X.
    Seddighzadeh, A.
    Sperling, B.
    Hung, S.
    Deykin, A.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 206 - 207
  • [35] A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis:: different response in drop-outs and treated patients
    Milanese, C
    La Mantia, L
    Palumbo, R
    Martinelli, V
    Murialdo, A
    Zaffaroni, M
    Caputo, D
    Capra, R
    Bergamaschi, R
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (12): : 1689 - 1692
  • [36] Assessment of long-term therapeutic adherence to IFN beta-1a (REBIF)® using the RebiSmart® electronic device in subjects with relapsing-remitting multiple sclerosis (RRMS)
    Fernandez Fernandez, O.
    Arroyo, R.
    Martinez-Yelamos, S.
    Marco, M.
    Garcia Merino, J. A.
    Munoz, D.
    Roque, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 824 - 824
  • [37] Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)
    Patti, Francesco
    Amato, Maria Pia
    Trojano, Maria
    Bastianello, Stefano
    Tola, Maria Rosalia
    Picconi, Orietta
    Cilia, Sabina
    Cottone, Salvatore
    Grimaldi, Luigi M. E.
    QUALITY OF LIFE RESEARCH, 2012, 21 (07) : 1111 - 1121
  • [38] Long-term treatment with subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: exploratory analysis of cumulative time and dose impact on clinical and magnetic resonance imaging outcomes
    Uitdehaag, B.
    Kappos, L.
    Verdun, E.
    Gardner, J.
    JOURNAL OF NEUROLOGY, 2009, 256 : S123 - S123
  • [39] Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
    Douglas L Arnold
    Peter A Calabresi
    Bernd C Kieseier
    Sarah I Sheikh
    Aaron Deykin
    Ying Zhu
    Shifang Liu
    Xiaojun You
    Bjoern Sperling
    Serena Hung
    BMC Neurology, 14
  • [40] Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
    Arnold, Douglas L.
    Calabresi, Peter A.
    Kieseier, Bernd C.
    Sheikh, Sarah I.
    Deykin, Aaron
    Zhu, Ying
    Liu, Shifang
    You, Xiaojun
    Sperling, Bjoern
    Hung, Serena
    BMC NEUROLOGY, 2014, 14
12345